Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, Professor of Medicine at the University of Central Florida, and at Loma Linda University Health, shared a post on LinkedIn:
“STOP CANCER 2026 – 2026 Summit for Novel Therapeutics, Early Drug Development in Oncology, and Precision Medicine in Cancer.
I am pleased to participate as faculty from the AdventHealth Cancer Institute and AdventHealth Central Florida, alongside an outstanding group of speakers.
The meeting will focus on novel antibody-drug conjugates (ADCs), targeted therapies, and emerging treatments directed at p53, PRMT5, and RAS, as well as other innovative therapeutic strategies currently being evaluated in clinical trials.
The program also covers advances in the treatment of:
- Lung cancer
- Breast cancer
- Colorectal cancer
- Prostate cancer
- Bladder cancer
- Kidney cancer
- Tumor-agnostic cancers
Review the agenda and register to learn more about the latest developments in oncology drug development and precision medicine.”
Other articles about Lung cancer on OncoDaily.
